Using the economic complexity methodology on data for disease prevalence in 195 countries during the period of 1990-2016, we propose two new metrics for quantifying the relatedness between diseases, or the 'disease space' of countries. With these metrics, we analyze the geography of diseases and empirically investigate the effect of economic development on the health complexity of countries. We show that a higher income per capita increases the complexity of countries' diseases. Furthermore, we build a disease-level index that links a disease to the average level of GDP per capita of the countries that have prevalent cases of the disease. With this index, we highlight the link between economic development and the complexity of diseases and illustrate, at the disease-level, how increases in income per capita are associated with more complex diseases.
Based on the ECI methodology, a number of recent contributions explain economic development and growth as a process of information development and of learning how to produce and export more diversified products [1, 4, 20, 21, 28, 29, 38, 56-58, 61, 62, 91, 93, 102] . Furthermore, Hartmann et al. [55] have recently shown that countries exporting complex products tend to be more inclusive and have lower levels of income inequality than countries exporting simpler products. In addition, Lapatinas and Litina [71] find that countries with high intellectual quotient (IQ) populations produce and export more sophisticated/complex products, while Lapatinas [70] shows that the Internet has a positive effect on economic complexity. Adopting the economic complexity methodology, Balland and Rigby [10] compute a knowledge complexity index with more than two million patent records for US metropolitan areas between . They analyze the geography and evolution of knowledge complexity in US cities and show that the most complex cities in terms of patents are not always those with the highest rates of patenting. In addition, using citation data, they show that more complex patents are less likely to be cited than simpler patents when the citing and cited patents are located in different metropolitan areas.
In this paper, we build a complexity index that measures the composition of a country's pool of prevalent cases of diseases by combining information on the diversity of diseases in the country and the ubiquity of its diseases (the number of other countries that also have prevalent cases of that disease). The intuition is that relatively high scores on the health complexity index indicate populations that are diverse and have diseases that, on average, have low ubiquity, i.e., these diseases have prevalent cases in only a few other countries.
In this view, the health complexity index does not refer to a complex treatment or to complex causes of a disease, but measures instead whether a disease is located in the densely connected core of the disease space i.e., whether many other related diseases have prevalent cases in many other countries. The country-disease network and the disease space reveal information about the health-related habits of populations, such as, lifestyle and dietary habits. There are also multiple 4/50 A. Garas, S. Guthmuller, and A. Lapatinas: The development of nations conditions the disease space reasons to expect the disease structures to be associated with their 'structural transformations' (i.e., the industrialization process by which economies diversify from agriculture to manufacturing and services [47, 59, 60, 68, 81] ), with their environmental performance [24, 63, 66, 67] , or with their adopted health-related policies [33, 41, 46, 76, 106] , as these contribute to their health status and living standards [42, 75] .
The aim of this paper is fourfold: (i) to build two new metrics that quantify the disease space, following the economic complexity methodology; (ii) to estimate the effect of economic development on countries' health complexity using the new metrics and following dynamic panel data econometric techniques; (iii) to develop a disease-level index that links a disease to the average level of GDP per capita of the countries in which the disease has prevalent cases; (iv) to illustrate how a country's economic development is associated with changes in its disease composition and verify the relationship between economic development and health complexity at the disease level.
The remainder of the paper is structured as follows. Section 2 describes the data on disease prevalence and the construction of the country-disease network and the disease space which form the analytical backbone of our study. Section 3 presents the methodology for developing the Health Complexity Index (HCI) and the Disease Complexity Index (DCI). Section 4 presents the results of the structural analysis of the disease space and the country-disease network, with a particular focus on countries and regions. Section 5 empirically investigates the effect of economic development on health complexity using the HCI, data on GDP per capita and potential covariates. Section 6 introduces an index that decomposes economic performance at the disease level.
Using this index, we highlight the link between disease complexity and economic development.
We demonstrate, at the disease level, that better economic performance is associated with more complex diseases. Finally, in section 7, we offer some concluding remarks.
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2 The country-disease network
Data on prevalent cases of diseases
Information on diseases comes from the 2016 Global Burden of Diseases (GBD) study by the Institute for Health Metrics and Evaluation (IHME), an independent population health research center at UW Medicine (University of Washington) [45] that collects data from various sources to examine, among other things, the prevalence of diseases and injuries across the world (http: //www.healthdata.org/).
Diseases and injuries are grouped by causes. The broader classification of causes (level 1) includes: (a) communicable, maternal, neonatal, and nutritional diseases such as HIV/AIDS and sexually transmitted infections, respiratory infections and tuberculosis, enteric infections (e.g., diarrheal diseases, typhoid fever), neglected tropical diseases (e.g. malaria, chagas disease) and other infectious diseases (e.g. meningitis and acute hepatitis), maternal and neonatal disorders (e.g., maternal abortion and miscarriage, ectopic pregnancy, maternal obstructed labor and uterine rupture), nutritional deficiencies (e.g., protein-energy malnutrition, vitamin A, iron, iodine deficiencies); (b) non-communicable diseases such as cancers, cardiovascular diseases, chronic respiratory diseases, digestive diseases (e.g., cirrhosis, gastritis, pancreatitis), neurological disorders (e.g., multiple sclerosis, epilepsy, Parkinson's and Alzheimer's diseases, migraine), mental disorders (e.g., schizophrenia, anorexia nervosa and bulimia nervosa, conduct and hyperactivity disorders), substance use disorders (e.g., alcohol and drug use disorders), diabetes, kidney diseases, skin diseases (e.g., dermatitis, bacterial skin diseases), sense organ diseases (e.g., glaucoma, cataract, vision loss), musculoskeletal disorders (e.g., osteoarthritis, rheumatoid arthritis); (c) injuries such as transport injuries (e.g., pedestrian road injuries, cyclist and motorcyclist road injuries), unintentional injuries (e.g., falls, poisonings, exposure to mechanical forces), self-harm 6/50 and interpersonal violence (e.g., sexual violence, conflict and terrorism, executions). 2 We use information for the most detailed level of causes in the GBD taxonomy (i.e., level 4, and when there is no level 4 classification, we use level 3). For example, among the non-communicable diseases (level 1), neoplasms (level 2) include the following level 3 categories: lip and oral cavity cancer, nasopharynx cancer, other pharynx cancer, esophageal cancer, stomach cancer, colon and rectal cancer, liver cancer, gallbladder and biliary tract cancer, pancreatic cancer, larynx cancer, etc. Then, liver cancer includes the following level 4 subcategories: liver cancer due to hepatitis B, liver cancer due to hepatitis C, liver cancer due to alcohol use, liver cancer due to non-alcoholic steatohepatitis (NASH), liver cancer due to other causes. In this case, as level 4 categories are available, we consider the information for these categories.
Two measures of disease prevalence are exploited: the rate of prevalence (number of cases per 100,000 population) for all ages, and the age-standardized rate of prevalence to account for the differences in age structures across countries. This is useful because relative over-or underrepresentation of different age groups can obscure comparisons of age-dependent diseases (e.g., ischemic heart disease or malaria) across populations.
The country-disease bipartite network
Instrumental to our analysis is the bipartite network mapping of countries and diseases. Bipartite, or bi-modal networks are abundant in the scientific literature, with examples including the citytech knowledge network [10] , the city-firm network [44] , firm-projects networks [9] , predator-prey networks [5] , plants-pollinator networks [12] etc. Here, we use data from the 2016 Global Burden of Diseases study that assessed the disease burden of countries in the period of 1990 to 2016, and we generate an l × k country-diseases matrix E, were the matrix element E cd represents the prevalent cases for disease d per 100,000 population in country c.
The aforementioned matrix allows for the construction of an undirected, weighted county-disease network by linking each disease to the countries that have prevalent cases. These networks are very dense, and in order to visually explore their structure, we apply the Dijkstra algorithm [30] to extract a Maximum Spanning Tree (MST) that summarizes their structures. More precisely, the MST, which is usually considered as the backbone of the network, is a connected subgraph having l + k − 1 edges with the maximum total weight and without forming any loops.
In Figure 1 we illustrate the country-disease MST for 2016. From this MST, we can easily identify clusters of countries that are linked to specific types of diseases. The main node of the network is caries in permanent teeth (disease cause number 682). This disease is the most common disease across the world, as it is present in the majority of countries. It is also the disease with the highest number of prevalent cases worldwide (2.44 billion cases in 2016 [45] )
The disease space
The clustering of countries and diseases in the MST of the country-disease network already points towards relations in the prevalence of different diseases. To explore this further, we construct the disease space, similar to the product-space introduced by Hidalgo et al. [62] . More precisely, from the country-disease matrix E, we calculate the 'relative disease disadvantage' (RDD) matrix, as described in the methods section (Section 3). In total, a country c has a relative disease disadvantage in a particular disease d if the proportion of prevalent cases of disease d in the country's total pool of prevalent disease cases is higher than the proportion of prevalent cases of disease d in the pool of prevalent disease cases in the rest of the world. In this case, RDD cd ≥ 1.
Calculating the RDD for all country-disease pairs allows us to derive a matrix Φ, whose elements Φ i,j define a proximity measure between all pairs of diseases. This proximity measure reveals diseases that are prevalent in tandem, or in other words, with Φ, we measure the probability that a country c, which has a relative disease disadvantage in disease i, also has a relative disease 8/50 
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disadvantage in disease j. The proximity measure is defined as:
where
is the conditional probability of having a relative disease disadvantage in disease i if you have a relative disease disadvantage in disease j. Using the minimum of both conditional probabilities, we avoid issues of a rare disease having prevalent cases in only one country. Additionally, we make the resulting matrix Φ symmetric (see Figure 2 ). The proximity matrix is highly modular and its block structure reveals the presence of 'communities', i.e., groups of diseases that are expected to occur together.
Next, we map this matrix onto a network, where each disease is represented by a node and every matrix element represents a weighted and undirected link. Similar to the previous section, we start by applying Dijkstra's algorithm on matrix Φ which calculates the MST of the network.
Following the rationale of Hidalgo et al. [62] , we start from the strongest links that are not part of the MST and keep adding links to the network until the average degree is four. The resulting network is a visual representation of the disease space, which is shown in Figure 2 .
From Figure 2 , it is evident that in the disease space network, different disease categories are clustered together and, similar to the product space network of Hidalgo et al. [62] , the network is heterogeneous and follows a core-periphery structure. The external part of the network (the periphery) is mostly dominated by 'communicable, maternal, neonatal, and nutritional diseases'.
In Section 4, we show that these diseases are mostly prevalent in low-income countries. On the other hand, the core of the network is dominated by 'non-communicable diseases', which have more prevalent cases in high-income countries (see Figure 3 ).
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Methods

Health complexity index
To calculate health complexity and disease complexity, we combine information on prevalent cases of diseases and how common these diseases are across countries, following the economic complexity methodology, i.e., the formulas in the pioneering work of Hidalgo and Hausmann [61] . In short, let us assume that we have disease information for l number of countries and k diseases. With this information, we can fill an l × k diseases matrix E, so that matrix element E cd is country c's information for disease d. If there is no information for disease d in country c, then E cd = 0. From this matrix, it is easy to calculate the following ratio:
where X cd is the number of prevalent cases of disease d per 100,000 population in country c. Using this threshold value, we obtain the l × k matrix M, with matrix elements M cd = 1 if country c has a RDD in disease d, and zero otherwise. A visualization of the matrix M that is used to calculate the HCI and the DCI for this dataset is shown in Figure 8 . From this matrix, similar to Hidalgo and Hausmann [61] , we introduce the HCI as a measure of countries' disease structures. To obtain the HCI, we first calculate the l × l square matrixM. In short, matrixM provides information about links connecting two countries c and c , based on the prevalent cases of diseases in both. The matrix elementsM cc are computed as
where according to Hausmann et al. [57] , the HCI is calculated as
The HCI reflects the disease-composition of a country's pool of diseases, taking into account the composition of the pools of all other countries. Populations with diseases that have prevalent cases of diseases that occur in many other countries have relatively low health complexity scores, while more health-complex countries have a high prevalence of non-ubiquitous diseases. In other words, a country has a complex disease composition, i.e., it is health-complex, if its diseases have high prevalence in only a few other countries. The HCI is higher for countries with diseases located at the core of the 'disease-space' and lower for countries with diseases located at the periphery of the 'disease-space'.
Disease complexity index
In a similar manner, but placing the spotlight on diseases rather than countries, we can calculate the Disease Complexity Index (DCI). In this case, the k × k matrixM provides information about links connecting two diseases d and d , based on the number of countries in which both 14/50
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and if Q is the eigenvector ofM associated with the second largest eigenvalue, As discussed above, the HCI and DCI are computed using in X cd the number of prevalent cases of a disease (according to cause levels 3 or 4) per 100,000 population for 195 countries and for 196 diseases. The time-period covered is from 1990 to 2016. With the age-standardized data (see the discussion in Section 2.1), we also calculate the age-standardized health complexity index (AHCI) and the age-standardized disease complexity index (ADCI) by following the same formulas. We use the two indices as alternative measures when checking the robustness of our results. It should be noted here that the computation of the indices is based only on diseases for which a country 15/50
A. Garas, S. Guthmuller, and A. Lapatinas: The development of nations conditions the disease space has a RDD in terms of disease prevalence (the incidence matrix of the bipartite network linking countries to diseases, M, reflects whether or not a country has a RDD in a specific disease; see Figure 8 ). Table 1 lists the five diseases with the highest and lowest DCI scores averaged over the period of 1990-2016. 4 The geography of complex diseases Most of the communicable diseases for which low-income countries have a RDD > 1 also appear in the periphery (for example, 'Turner syndrome', 'neural tube defects' and 'pyoderma'). Examples of injuries for which low-income countries have a RDD include 'venomous animal contact' and 'sexual violence', which again appear in the periphery of the disease space.
The above descriptive findings are also observable in Figure 4 , where we map the spatial variation in complex diseases. This figure shows the repartition of the HCI across countries when taking average values for the period 1990-2016. We see rather clearly that disease complexity is unevenly distributed in the world and that the most complex countries in terms of diseases seem to be located in Europe, North America, and Australia -European countries, Australia, the US, and Canada belong to the set of countries with the highest HCI (>80%). In contrast, most countries in Africa have much lower HCIs on average. seems that a country's HCI score tends to persist through time, which is to be expected for a metric of prevalent cases of diseases aggregated at the country level. This motivates the inclusion of the lagged value of HCI in the set of explanatory variables when estimating the effect of economic development on health complexity in the next section.
The effect of economic development on health complexity
We study the effect of economic development on health complexity using data on GDP per capita 
Regression analysis
Previous research shows that there is a strong positive association between income and indicators of population health such as life expectancy and child mortality. There are various channels through which economic development can stimulate health improvements, for example, via its effect on nutrition (which in turn leads to better resistance to bacterial diseases and faster recovery from illnesses), as well as through greater labor market participation, worker productivity, investment in human capital, investment in public and private health services, savings, fertility, transportation infrastructure, and lifestyle habits. [6, 16, 17, 35, 43, 53, 73, 83, 87, 96] . 4 The term 'diseases of affluence' refers to selected diseases and health conditions that are more prevalent in wealthy nations. Examples include mostly non-communicable diseases such as cardiovascular diseases and their nutritional risk factors (overweight and obesity, elevated blood pressure and cholesterol). It has been shown that economic development is a robust predictor of 'diseases of affluence' [36, 50, 79, 90, 109] . However, there is also a large and growing literature that investigates the reverse channel, i.e., that better population health leads to economic development [2, 15] . The argument is that improved health conditions increase population size, which -in the medium term -leads to more people entering the labor force, higher capital accumulation, and higher income per capita.
In order to estimate the effect of economic development on the health complexity of countries we follow a fixed-effects two-stage least squares/instrumental variables (FE 2SLS/IV) strategy, complemented with a difference Generalized Method of Moments (diff-GMM) approach. We regress the baseline specification described by the following equation:
Here, the health complexity of country i in period t (HCI i,t ) depends on the country's level of economic development in per capita terms (in logs), GDP pc i,t . The lagged value of the dependent variable on the right-hand side is included to capture persistence in health complexity. The main variable of interest is GDP pc. The parameter β 1 therefore measures the effect of income per capita on health complexity. 5 Additional potential covariates are included in the vector controls i,t . The γ i 's denote a full set of country dummies and the δ t 's denote a full set of time effects that capture common shocks to the health complexity scores of all countries. The error term u i,t captures all other omitted factors, with E(u i,t ) = 0 for all i and t. To examine the robustness of our results and to generalize our findings, we replicate our analysis for additional/alternative control variables and substitute the HCI with the AHCI, finding qualitatively similar results (see 5 In order to account for possible changes in the relation between economic development and health complexity over the process of economic development, we have experimented with the inclusion of the quadratic specification of GDP per capita in the estimated equation. Our baseline results (which are available upon request) do not confirm a U-shaped relationship between economic development and health complexity. subection 5.2). 
Control Variables
We include in the estimated equation a number of control variables that are likely related to health complexity.
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The proportion of nations' populations over the age of 65 has been increasing in recent years and will continue to rise in future as a result of longer life expectancy. Population age-structure is a significant determinant of a nation's health status, due to age-related diseases (i.e., illnesses and conditions that occur more frequently in people as they get older). Examples of age-related diseases include cardiovascular and cerebrovascular diseases, hypertension, cancer, Parkinson's disease, Alzheimer's disease, osteoarthritis and osteoporosis. Demographic factors such as age and sex are considered key covariates in the study of human health and well-being, hence the percentage of old population (aged 65 and above, in logs) and the percentage of f emale population (in logs) are included in the set of control variables.
It has previously been shown that sex interacts with social, economic and biological determinants to create different health outcomes for males and females. For example, Vlassoff [104] reviews a large number of studies on the interaction between sex and the determinants and consequences of chronic diseases, showing how these interactions result in different approaches to prevention, treatment, and coping with illness.
In our analysis, we also control for the (log) percentage of urban population, urban. According to the World Health Organization (WHO), a large proportion of non-communicable diseases is linked to risks related to the urban environment, such as physical inactivity and obesity, cardiovascular and pulmonary diseases from transport-generated urban air pollution, ischemic heart disease and cancers from household biomass energy use, asthma from indoor air pollution, and heat-related strokes and illnesses. In addition, communicable diseases such as tuberculosis, dengue fever, and many respiratory and diarrheal diseases result from unhealthy urban environments (e.g. lack of adequate ventilation, unsafe water storage and poor waste management, indoor air pollution, moldy housing interiors, poor sanitation). 6 Industrialization, i.e., the structural transformation from agricultural to industrial production also has a range of significant health implications [23, 77, 97, 98, 101] . We capture these implications in our analysis by including the (log) value added of agriculture (% of GDP) and the (log) value added of manuf acturing (% of GDP) in the estimated equation.
To check the robustness of our baseline results, we replicate our analysis controlling also for the human capital of the population by utilizing total enrolment in secondary education (in logs). It is well established in the relevant literature that through education, people gain the ability to be effective in their lives. They adopt healthier lifestyles and inspire their offspring to do as well [78] .
Individuals with higher levels of education also tend to have better socioeconomic resources for a healthy lifestyle and a higher probability of living and working in healthy environments [3, 18] . In addition, educated individuals tend to have lower exposure to chronic stress [84] . Low educational attainment, on the other hand, is associated with a shorter life expectancy, poor self-reported health, and a high prevalence of infectious and chronic non-infectious diseases [37, 51, 72, 108] . 7 Furthermore, we re-estimate the baseline model by substituting urban with population density (people per square km of land, in logs).
The variable CO 2 (log of CO 2 emissions in kg per 2010 $US of GDP) captures the effect of air pollution on health, which has been the subject of numerous studies in recent years (for an extensive review, see [19] ).
Finally, health expenditure (log of total health spending in thousands of purchasing power parity (PPP)-adjusted 2017 $US) is also included in the set of explanatory variables controlling for the association between healthcare spending and health outcomes [11, 27, 74, 82, 94, 105, 107, 111] Data definitions, sources and summary statistics for the variables included in the analysis are given in Table 2 .
Instrumental variables
We estimate equation (7) using different econometric methods. First, we use fixed-effects OLS.
However, fixed effects estimators do not necessarily identify the effect of economic development on health complexity. The estimation of causal effects requires exogenous sources of variation.
While we do not have an ideal source of exogenous variation recognized by previous studies, there are two promising potential instruments of economic development that we adopt in our fixed-effects 2SLS/IV and diff-GMM analyses.
First, we use the KOF Swiss Economic Institute's economic globalization index, characterized as the flows of goods, capital, and services, as well as information and perceptions that accompany market exchanges [31] . Higher values reflect greater economic globalization.
The second instrument considered is the KOF Swiss Economic Institute's political globalization index, characterized by the number of embassies in a country, its membership in international organizations, its participation in UN security council missions and international treaties. Higher values reflect greater political globalization.
There is extensive research documenting the positive relationship between globalization and economic development and growth [22, 31, 34, 48, 52] . While we do not have a precise theory to support the prediction, it is expected that changes in the economic globalization and political globalization indices have no direct effect on a country's disease structure and impact health complexity only indirectly, through the channel of economic development. This point is also verified in our dataset, as we find no correlation between HCI scores and these two variables (the results are available upon request). 
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Regression results
In this section, we discuss the results of estimating equation (7) with different econometric techniques. Table 3 reports the results of fixed-effects ordinary least squares (FE-OLS) with time dummies, adding an additional variable from the set of controls in each step (column). In all specifications, economic development has a positive relationship with health complexity, and the control variables enter with the expected sign. The agriculture coefficient is negative, and countries with a higher proportion of urban population exhibit greater health complexity.
The results depicted in Table 3 could only be interpreted as correlations. For a robust analysis accounting for the potential endogeneity problem in the relationship under consideration (discussed above), we use fixed-effects 2SLS/IV estimation techniques complemented with diff-GMM estimations à la Arellano-Bond [8] . Table 4 presents our baseline results.
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In columns (1)- (8), we estimate equation (7) with FE 2SLS/IV regressions. We use time dummies and robust standard errors (in parentheses). In all cases, GDP pc is a positive and statistically significant predictor of health complexity. In fact, we find that an increase in GDP per capita of 10% is associated with an improvement of about 0.003 in the HCI (standard deviation: 1.004).
This positive impact of economic development on health complexity is robust to the inclusion of control measures discussed in subsection 5.1.1. The statistically significant urban coefficient implies that a higher proportion of urban population is associated with more complex diseases.
In the fixed effects 2SLS/IV estimations we report: (a) the F -test for the joint significance of the instruments in the first stage: the rule of thumb is to exceed 10, hence the test implies weak significance [100] ; (b) the Durbin-Wu-Hausmann (DW H) test for the endogeneity of regressors: the null hypothesis that the IV regression is not required is rejected; (c) the Cragg-Donald Fstatistic (W eak-id), testing the relevance of the instruments in the first-stage regression: no evidence of a low correlation between instruments and the endogenous regressor is found after controlling for the exogenous regressors; (d) the Kleibergen-Paap Wald test (LM -weakid) of weak identification: the null hypothesis that the model is weakly identified is rejected; (e) the p-value for Hansen's test of overidentification: the acceptance of the null indicates that the overidentifying restrictions cannot be rejected.
In column (9) of Table 4 we report the diff-GMM estimations including year fixed effects and robust standard errors. The results verify the previous findings both qualitatively and quantitatively, i.e., the estimated coefficient of GDP pc implies an improvement of 0.003 in the HCI with a GDP per capita increase of 10%. Among the control variables, only the urban variable has a statistically significant and positive sign. The values reported for AR(1) and AR(2) are the p-values for first-and second-order autocorrelated disturbances. As expected, there is high first-order autocorrelation and no evidence for significant second-order autocorrelation. Hence, our test statistics hint at a proper specification. (1) (2) (3) (4) (5) (6) (7) (8) (9) FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV diff-GMM 0.681 AR (1) 0.000 AR (2) 0.158 Note: Dependent variable: Age-standardized Health Complexity Index (AHCI). Main independent variable: GDP per capita in logs (GDP pc). Columns (1) In Tables 5 and 6 , we investigate the robustness of our baseline findings. First, we substitute the HCI with the age-standardized health complexity index (AHCI) maintaining the same set of controls (and time dummies) as in the baseline specification. Second, we investigate whether the positive impact of economic development on health complexity persists under additional
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A. Garas, S. Guthmuller, and A. Lapatinas: The development of nations conditions the disease space and/or alternative control measures (including time dummies). In all cases, the baseline results remain qualitatively intact. In particular, the coefficient of GDP pc is positive and statistically significant in the instrumented regressions (see Table 5 ; to save space, we only include the firststage estimated coefficients of the instruments -the results for the rest of the variables are available upon request). Table 6 starts from the baseline specification with the full set of controls [column (9) in Table   4 ] and introduces additional variables or alternative measures for some of the previous controls.
Specifically, in column (1), we add education (enrolment in secondary education in logs). In column (2), we substitute the urban population variable with population density (people per sq.
km of land in logs). In columns (3) and (4), we employ (log) CO 2 emissions (CO 2 emissions, kg per 2010 $US of GDP) and (log) health expenditure (total health spending, thousands of 2017 PPP adjusted $US), respectively. Finally, in column (5), we consider all of the above variables together.
Adding these controls in our estimations leaves the findings qualitatively and quantitatively intact.
The above analysis suggests that economically developed countries tend to exhibit more complex disease structures. Furthermore, exploiting the temporal variation in the data, the fixed-effects 2SLS/IV analysis and the difference GMM estimators reveal a positive, statistically significant, and robust impact of economic development on health complexity.
Economic development and disease complexity
The economic complexity methodology provides a useful toolbox that allows us to compute indices that quantify the complexity of both countries and diseases. For example, using the same methodology that computes the HCI, but placing the spotlight on diseases rather than countries, , where a dark point indicates that country c has a RDD in a given disease d. The matrix is sorted using the NODF algorithm [7] , which highlights the existence of countries that are very well diversified and countries that have prevalent cases only for a small set of diseases.
mann et al. [55] recently introduced a measure that associates products with income inequality and showed how the development of new products is associated with changes in income inequality. Here, to decompose economic development at the disease level, we introduce a measure that links a disease to the average income per capita of the countries in which the disease has prevalent cases i.e., an estimate of the expected income per capita related to different diseases. In this way, we illustrate how disease complexity is being affected by the level of economic development and quantify the relationship between countries' income per capita and the complexity of their diseases.
Following the methodology in Hartmann et al. [55] , we define the Disease-Income Complexity Index (DICI), and decompose the relationship between the DCI and the DICI for the prevalent cases of diseases in our sample of countries. 8 
Disease-income complexity index
Assuming that we have information for l countries and k diseases, we can fill the (l × k) matrix 
where X cd is the number of prevalent cases per 100,000 population for disease d in country c, while d X cd is the number of prevalent cases of all diseases in country c. If GDP c is the (log)
GDP per capita of country c, we can calculate the DICI d for every disease d as:
The DICI is defined at the disease level as the average level of (log) GDP per capita of the countries that have a RDD in disease d, weighted by the disease's importance in each country's pool of diseases. Utilizing the (log) PPP GDP per capita (constant 2011 international $) from the World Bank's World Development Indicators for the countries in our sample, we calculate the above index for every year in the period of 1990-2016. The statistically significant positive correlation between the DICI and the DCI indicates that more complex diseases are associated with more developed countries, as measured by the (log)
GDP per capita. This allows us to understand which sets of diseases are linked to better overall economic performance, based on their complexity.
In Table 8 , we run panel regressions between the DCI and DICI. The results show that the relationship between the DCI and the DICI is the outcome of the correlations both between diseases (regression on group means) and within diseases (fixed-effects regression with time dummies and standard errors adjusted for disease clusters). This suggests that the positive effect of economic development on the complexity of diseases is due to both changes in the structure of the disease space towards more complex diseases and increases in the complexity of existing diseases. 
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Conclusions
Our analysis illustrates that a country's level of development determines the structure of its disease space. Following the economic complexity methodology, we developed the HCI, which quantifies the network representation of the relatedness and proximity of diseases. In a dynamic panel data setting, we showed that there is a robust positive effect of a country's economic development, measured by GDP per capita, on its level of health complexity, i.e., on the 'structural' composition of its pool of diseases. The evidence presented here suggests that the economic development of nations conditions the disease space. Specifically, more complex diseases tend to have relatively more prevalent cases in populations with a higher income per capita. Explicitly, it seems that when an economy accelerates, the impact on health complexity is positive.
In addition, we build the DICI, which links a disease to the average level of income per capita of the countries in which the disease has prevalent cases and illustrate how disease complexity is related to economic development. Specifically, we show how changes in GDP per capita are associated with more complex diseases. The temporal variation of the above indices is important from a policy perspective. Using the HCI and DCI, it is possible to design policies aimed at improving 37/50 the recognition, visibility, and traceability of complex diseases across the globe and through time (e.g., by developing a classification system for all health information systems). These indices can also be used as tools for the development of national plans for complex diseases and the establishment of knowledge networks on complex diseases, so as to improve their diagnosis, treatment, and cure. Furthermore, the DICI could be used to design a health expenditure reallocation policy promoting health activities and services associated with the prevention of complex diseases.
This study employs the economic complexity methodology to compute two new metrics that quantify the disease space of countries. These can be valuable tools for estimating the effect of economic development on the health status of nations. The topic of economic complexity is a rather new one, and its use in economics is rather limited so far. By focusing on the topic of disease complexity, our contribution lies in bridging the health economics literature with the literature that highlights economic complexity as a powerful paradigm in understanding key issues in economics, geography, innovation studies, and other social sciences.
